SA519410534B1 - أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها - Google Patents
أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتهاInfo
- Publication number
- SA519410534B1 SA519410534B1 SA519410534A SA519410534A SA519410534B1 SA 519410534 B1 SA519410534 B1 SA 519410534B1 SA 519410534 A SA519410534 A SA 519410534A SA 519410534 A SA519410534 A SA 519410534A SA 519410534 B1 SA519410534 B1 SA 519410534B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- lymphocyte attenuator
- agonist antibodies
- antibodies
- treatment
- attenuator
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508510P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/032218 WO2018213113A1 (en) | 2017-05-19 | 2018-05-11 | Btla agonist antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SA519410534B1 true SA519410534B1 (ar) | 2023-11-08 |
Family
ID=62245543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SA519410534A SA519410534B1 (ar) | 2017-05-19 | 2019-11-12 | أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10604573B2 (enExample) |
| EP (1) | EP3625257A1 (enExample) |
| JP (2) | JP6790304B2 (enExample) |
| KR (3) | KR102294051B1 (enExample) |
| CN (3) | CN110621699B (enExample) |
| AR (1) | AR111752A1 (enExample) |
| AU (2) | AU2018269585B2 (enExample) |
| BR (1) | BR112019021547A2 (enExample) |
| CA (2) | CA3184628A1 (enExample) |
| CL (1) | CL2019003215A1 (enExample) |
| CO (1) | CO2019012756A2 (enExample) |
| CR (1) | CR20190521A (enExample) |
| DO (1) | DOP2019000293A (enExample) |
| EA (1) | EA201992460A1 (enExample) |
| EC (1) | ECSP19082184A (enExample) |
| JO (1) | JOP20190261A1 (enExample) |
| MA (1) | MA49133A (enExample) |
| MX (1) | MX381033B (enExample) |
| MY (2) | MY197425A (enExample) |
| NZ (1) | NZ758360A (enExample) |
| PE (1) | PE20191843A1 (enExample) |
| PH (1) | PH12019502575A1 (enExample) |
| SA (1) | SA519410534B1 (enExample) |
| TW (4) | TWI804044B (enExample) |
| WO (1) | WO2018213113A1 (enExample) |
| ZA (1) | ZA201906954B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201820554D0 (en) * | 2018-12-17 | 2019-01-30 | Univ Oxford Innovation Ltd | BTLA antibodies |
| EP4045641A1 (en) | 2019-10-15 | 2022-08-24 | Eli Lilly and Company | Recombinantly engineered, lipase/esterase-deficient mammalian cell lines |
| GB202008860D0 (en) * | 2020-06-11 | 2020-07-29 | Univ Oxford Innovation Ltd | BTLA antibodies |
| IL302135A (en) * | 2020-10-23 | 2023-06-01 | Anaptysbio Inc | B and t lymphocyte attenuator (btla) modulators and method of using same |
| MX2024009326A (es) * | 2022-01-29 | 2024-08-06 | Hifibio Inc | Anticuerpos anti-btla y usos de los mismos en el tratamiento del cancer. |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024243594A1 (en) * | 2023-05-25 | 2024-11-28 | Anaptysbio, Inc. | Btla agonist for mudulation of dendritic cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8546541B2 (en) | 2002-06-20 | 2013-10-01 | Washington University | Compositions and methods for modulating lymphocyte activity |
| EP1560593B1 (en) * | 2002-10-25 | 2016-04-20 | Genentech, Inc. | Novel composition and methods for the treatment of immune related diseases |
| CA2669921A1 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to btla and methods of use |
| EP2459594A1 (en) * | 2009-07-31 | 2012-06-06 | N.V. Organon | Fully human antibodies to btla |
| US9533039B2 (en) * | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| WO2014018931A1 (en) * | 2012-07-26 | 2014-01-30 | The General Hospital Corporation | Methods and compositions for treating autoimmune disease |
| WO2014183885A1 (en) * | 2013-05-17 | 2014-11-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antagonist of the btla/hvem interaction for use in therapy |
| JP2018521959A (ja) * | 2015-04-29 | 2018-08-09 | サンフォード−バーナム メディカル リサーチ インスティテュート | Ｂｔｌａアゴニスト抗体を用いた免疫応答のモジュレーション |
| JP7227007B2 (ja) * | 2015-12-02 | 2023-02-21 | ストサイエンシス， インコーポレイテッド | グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体 |
-
2017
- 2017-06-16 JO JOP/2019/0261A patent/JOP20190261A1/ar unknown
-
2018
- 2018-05-03 AR ARP180101158A patent/AR111752A1/es not_active Application Discontinuation
- 2018-05-04 TW TW110141711A patent/TWI804044B/zh active
- 2018-05-04 TW TW107115166A patent/TWI677504B/zh not_active IP Right Cessation
- 2018-05-04 TW TW108133289A patent/TWI747043B/zh not_active IP Right Cessation
- 2018-05-04 TW TW112116965A patent/TW202334237A/zh unknown
- 2018-05-11 CN CN201880033180.XA patent/CN110621699B/zh active Active
- 2018-05-11 MA MA049133A patent/MA49133A/fr unknown
- 2018-05-11 BR BR112019021547-6A patent/BR112019021547A2/pt unknown
- 2018-05-11 CA CA3184628A patent/CA3184628A1/en active Pending
- 2018-05-11 JP JP2020511876A patent/JP6790304B2/ja active Active
- 2018-05-11 MY MYPI2019006702A patent/MY197425A/en unknown
- 2018-05-11 KR KR1020197033639A patent/KR102294051B1/ko active Active
- 2018-05-11 US US15/977,003 patent/US10604573B2/en active Active
- 2018-05-11 PE PE2019002417A patent/PE20191843A1/es unknown
- 2018-05-11 EP EP18727622.5A patent/EP3625257A1/en active Pending
- 2018-05-11 KR KR1020217026470A patent/KR20210106033A/ko not_active Ceased
- 2018-05-11 CA CA3064518A patent/CA3064518A1/en active Pending
- 2018-05-11 EA EA201992460A patent/EA201992460A1/ru unknown
- 2018-05-11 WO PCT/US2018/032218 patent/WO2018213113A1/en not_active Ceased
- 2018-05-11 NZ NZ758360A patent/NZ758360A/en not_active IP Right Cessation
- 2018-05-11 CN CN202311364322.XA patent/CN117402245A/zh active Pending
- 2018-05-11 KR KR1020227039792A patent/KR20220158847A/ko not_active Ceased
- 2018-05-11 CN CN202311364321.5A patent/CN117402244A/zh active Pending
- 2018-05-11 CR CR20190521A patent/CR20190521A/es unknown
- 2018-05-11 MX MX2019013604A patent/MX381033B/es unknown
- 2018-05-11 MY MYPI2021007625A patent/MY198277A/en unknown
- 2018-05-11 AU AU2018269585A patent/AU2018269585B2/en active Active
-
2019
- 2019-10-22 ZA ZA2019/06954A patent/ZA201906954B/en unknown
- 2019-11-08 CL CL2019003215A patent/CL2019003215A1/es unknown
- 2019-11-12 SA SA519410534A patent/SA519410534B1/ar unknown
- 2019-11-15 CO CONC2019/0012756A patent/CO2019012756A2/es unknown
- 2019-11-15 DO DO2019000293A patent/DOP2019000293A/es unknown
- 2019-11-18 PH PH12019502575A patent/PH12019502575A1/en unknown
- 2019-11-18 EC ECSENADI201982184A patent/ECSP19082184A/es unknown
-
2020
- 2020-02-17 US US16/792,396 patent/US11396545B2/en active Active
- 2020-11-04 JP JP2020184527A patent/JP7072622B2/ja active Active
-
2021
- 2021-12-02 AU AU2021277743A patent/AU2021277743A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519410534B1 (ar) | أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها | |
| CL2020000938A1 (es) | Anticuerpos anti-tigit, sus composiciones y uso. (divisional solicitud 201800744) | |
| CY1123409T1 (el) | Αντισωματα κατα toy icos (επαγωγιμος συνδιεγερτης τ-κυτταρων) | |
| MX374853B (es) | Anticuerpos anti-proteína que contiene domino de inmunologlubina relacionado con el receptor de poliovirus (pvrig) y metodos de uso. | |
| MX2021012307A (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y metodos para su uso. | |
| MX2020000960A (es) | Anticuerpos anti-tigit. | |
| PE20191812A1 (es) | Compuestos y metodos para la reduccion celular especifica de tumor | |
| CO2022004797A2 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso | |
| MX2020003132A (es) | Anticuerpos anti-ctla4 y usos de los mismos. | |
| EA202190609A1 (ru) | Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g | |
| EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
| MX2021007768A (es) | Anticuerpos anti-ctla4 y metodos de uso de los mismos. | |
| CR20170383A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd-123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| JOP20200343A1 (ar) | بروتين ربط مولد ضد مضاد لـ steap1 | |
| MX2017003478A (es) | Anticuerpos anti-fgfr2/3 y metodos para su uso. | |
| EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
| UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| EA201792220A1 (ru) | Опосредуемая антителом нейтрализация вируса чикунгунья | |
| CR20200404A (es) | Anticuerpos anti-klk5 y métodos de uso | |
| EA201791691A1 (ru) | ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d | |
| EA201990253A1 (ru) | Гуманизированные антитела против s100a9 и их применение | |
| MX2018000073A (es) | Agonistas de proteina de fusion btla y usos de los mismos. | |
| EA201792312A1 (ru) | Конструкции на основе калихеамицина и способы их применения | |
| EA202090309A1 (ru) | Анти-tigit антитела | |
| EA202090929A1 (ru) | Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения |